Empresas›XLO

XLO · Xilio Therapeutics, Inc.

preparados farmaceuticos · CIK 0001840233

Xilio Therapeutics, Inc. (XLO) cotiza en el NASDAQ y se dedica a preparados farmaceuticos. Aqui estan 5 documentos que ha presentado ante la SEC, desde 18 may 2026. En sus informes aparecen frases que este sitio vigila: contrasplit de acciones y programa de venta continua de acciones (atm). Estan citadas literalmente mas abajo.

Documentos

5

recogidos hasta hoy

Ultimo

12 ago 2026

Registro de acciones para empleados

Todavia no se publican los trimestres de caja ni la dilucion de esta empresa: hacen falta datos de sus informes que solo se recogen de las que se siguen de cerca. Lo que ves abajo son sus documentos tal y como los presento ante la SEC.

Documentos presentados ante la SEC

2026

1. 12 ago 2026S-8Registro de acciones para empleadosEDGAR
2. 12 ago 202610-QInforme trimestralEDGAR
   Contrasplit de accionesver la frase en el documento (ingles)

   …The results for the three and six months ended June 30, 2026 are not necessarily indicative of the results for the year ending December 31, 2026 or for any future period. On March 13, 2026, the Company effected a reverse stock split of its common stock at a ratio of 1-for-14. The reverse stock split did not impact the number of authorized shares of common stock or preferred stock or the par value per share of the common stock or…

   Programa de venta continua de acciones (ATM)ver la frase en el documento (ingles)

   …additional total gross proceeds by the end of 2026, before deducting underwriting discounts and commissions and any offering expenses. Sales Agreement and “At-The-Market” Facility In March 2025, the Company entered into an “at-the-market” (“ATM”) facility with Leerink Partners, LLC (“Leerink”) pursuant to which the Company could initially issue and sell shares of its common stock from time to time at an aggregate offering price of up to $50.0 million through…
3. 12 ago 20268-KHecho relevanteEDGAR
   Contrasplit de accionesver la frase en el documento (ingles)

   …share, basic and diluted $ (0.33) (2.30) $ (0.89) $ (4.76) Weighted average common shares outstanding, basic and diluted (3) 19,404,688 6,889,119 17,884,542 6,116,721 (1) On March 13, 2026, the company effected a 1-for-14 reverse stock split of its common stock. All share amounts and per share amounts in this press release have been adjusted retroactively to reflect the reverse stock split for the periods presented. (2) Operating expenses…
4. 27 may 2026CORRESPCorrespondencia con la SECEDGAR
5. 18 may 2026UPLOADCarta de comentarios de la SECEDGAR